Unit 18, 6th Floor
Building 21 No. 388 Xinping Street Suzhou Industrial Park
Suzhou
China
86 10 8414 8018
https://www.canbridgepharma.com
Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees: 118
Name | Title | Pay | Exercised | Year Born |
---|---|---|---|---|
Dr. James Qun Xue M.B.A., Ph.D. | Founder, Chairman of the Board, CEO & Member of Strategic Advisory Board | 5.52M | N/A | 1970 |
Mr. Glenn Hassan | Chief Financial Officer | N/A | N/A | 1979 |
Dr. Pauline Li M.B.A., M.D. | Senior VP of Clinical Development & Operations | N/A | N/A | N/A |
Ms. Qian Ma | Director of Legal & Compliance, Board Secretary and Joint Company Secretary | N/A | N/A | N/A |
Ms. Stella Mao | Senior Director of Public Affairs | N/A | N/A | N/A |
Ms. Chris Chen | Vice President of Human Resources | N/A | N/A | N/A |
Dr. Gerald F. Cox M.D., Ph.D. | Chief Development Strategist & Interim Chief Medical Officer | N/A | N/A | 1959 |
Mr. Marcelo Cheresky | Chief Commercial Officer | N/A | N/A | 1966 |
Dr. Wei Zhang | Senior Director & Head of CMC China | N/A | N/A | N/A |
Ms. Rebecca Zhang | Senior Vice President of Regulatory Affairs | N/A | N/A | N/A |
CANbridge Pharmaceuticals Inc., a biopharmaceutical company, engages in the research, development, and commercialization of therapies for rare diseases and oncology indications worldwide. The company offers Hunterase, an enzyme replacement therapy for the treatment of Hunter syndrome; NERLYNX (Neratinlib), a potent irreversible tyrosine kinase inhibitor for HER2-positive breast cancer; and Caphosol Mouth Rinse for temporary and persistent dryness of the mouth and throat. It also engages in the development of CAN008, a glycosylation fusion protein that blocks the interaction between the CD95 receptor and its cognate ligand CD95L through binding to CD95L; CAN108, an orally administered small molecule ASBT inhibitor; CAN106, a recombinant human monoclonal antibody that specifically binds to and neutralizes C5 in the complement system; CAN103, a recombinant human enzyme replacement therapy (ERT); CAN107, a fibroblast growth factor 23 (FGF23) blocking antibody; CAN104, a recombinant human ERT; CAN105, a bispecific antibody; CAN201, a gene therapy program that utilizes adeno-associated virus (AAV) sL65 capsid; and CAN202, a gene therapy program utilizing AAV sL65 capsid. CANbridge Pharmaceuticals Inc. was founded in 2012 and is headquartered in Suzhou, China.
CANbridge Pharmaceuticals Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.